Beam Therapeutics (BEAM) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Beam Therapeutics

NasdaqGS•Healthcare•Biotechnology

$24.95+0.28(0.01%)Market closed

Market Cap

$2.60B

P/S

16.7x

P/B

2.4x

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

How this company scores

AverageMetricSide Score: 54/100

Strongest: Growth (19/25); weakest: Cash & Earnings Quality (6/25).

Profitability10/25

Growth19/25

Balance Sheet & Red Flags19/25

Cash & Earnings Quality6/25

Strengths

Growing revenueLow leverageProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 16.7x5y range 5.5x – 7530.3x

Currently below its 20-quarter median.

P/B · 2.4x5y range 1.5x – 6.8x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.60B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $156.03M
Q. Revenue: $490,000
TTM EBITDA: $-355.78M
TTM Op. Income: $-378.02M
Q. Op. Income: $-126.55M
TTM Net Income: $-85.43M
Q. Net Income: $-122.68M
EPS: $-1.18
Shares Out.: $104.33M

$156.03M in TTM revenue grew 158.9% YoY, reaching $490,000 last quarter. TTM EBITDA of $-355.78M and TTM operating income of $-378.02M show growth is flowing through to the bottom line. However, net income is negative at $85.43M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 159% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -24723.1%
Op. Margin: -25827.1%
Net Margin: -25036.3%

Op. margin of -25827.1% is down 24407.9% YoY — costs are rising relative to revenue. Net margin at -25036.3% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 16.7x
P/B Ratio: 2.4x

P/S of 16.7x and P/B of 2.4x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.39B
Cash: $219.82M
Long-Term Debt: $100.26M
Book Value: $1.07B
D/E Ratio: 0.1
Debt/EBITDA: N/A

With $1.39B in assets and $100.26M in long-term debt, D/E is 0.1and book value is $1.07B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 0% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-66.10M
TTM Free Cash Flow: $-372.77M
FCF Margin: -238.9%
FCF / Net Income: 4.4

TTM FCF of $-372.77M on $-66.10M in operating cash flow. The FCF / Net Income ratio of 4.4x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 5% — an improving trend.